Fundraising Fox

Jason Rhodes

Investor

Partner at Atlas Venture

Cambridge, Massachusetts, United States

Writes $500K – $5M checks · typically $2M

About

Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.

Invests in

Biotech

Experience

  1. American Academy in RomeTrusteecurrent2026 — present
  2. Atlas VenturePartnercurrent2014 — presentCambridge, MA
  3. Rectify PharmaExecutive Chair (and founding CEO)current2020 — present
  4. Dyne TherapeuticsChairman (and founding CEO)current2017 — presentCambridge, MA
  5. Berklee College of MusicPresidential Advisory Council, Member2009 — 2022
  6. Disarm Therapeutics (acquired by Lilly in 2020)Chairman (and founding CEO)2016 — 2020
  7. EpizymePresident and CFO2010 — 2014NASDAQ: EPZM www.epizyme.com
  8. AlnylamVice President, Business Development2007 — 2010
  9. Fidelity Biosciences(F-Prime)Partner2001 — 2007

Education

  1. Yale UniversityBA, History - modern diplomatic and financial history
  2. The Wharton SchoolMBA

Skills & more

Strategy69Leadership9Management6Strategic Planning6Venture Capital82Corporate Development33Alliances2Investments13Life Sciences32Biotechnology65Strategic Partnerships63Business Alliances6
+12 moreOncologyMergersPrivate EquityDrug DiscoveryLifesciencesTechnology TransferPharmaceutical IndustryCommercializationBusiness DevelopmentStrategic AlliancesProduct DevelopmentProduct Management

From Jason's professional profile.

Same school

Shared employers

Investments

Led

FoldRx

Board seats

AAVantgarde BioAccent TherapeuticsDisarm TherapeuticsDyne TherapeuticsK36 TherapeuticsKaryoVerseMithrilRectify PharmaceuticalsWeaver

Per the firm's website.

Colleagues at Atlas Venture

Network5

Investors connected to Jason in public investor directories — a warm-intro map.